Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments

Claudia Marchetti, Giovanni Scambia, Anna Fagotti, Luigi Michele Antonio Romito, Valentina Iacobelli, Giacomo Corrado, Caterina Ricci, Francesca De Felice, Alessia Romito, Carolina Maria Sassu

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Ovarian cancer (OC) remains a fatal malignancy because most patients experience recurrent disease, which is resistant to chemotherapy. The outcomes for patients with platinum-resistant OC are poor, response rates to further chemotherapy are low and median survival is lower than 12 months. The complexity of platinum-resistant OC, which comprises a heterogeneous spectrum of diseases, is indeed far from being completely understood. Therefore, comprehending tumors’ biological behaviour to identify reliable biomarkers, which may predict responses to therapies, is a demanding challenge to improve OC management. In the age of precision medicine, efforts to overcome platinum resistance in OC represent a dynamic and vast field in which innovative drugs and clinical trials rapidly develop. This review will present the exceptional biochemical environment implicated in OC and highlights mechanisms of chemoresistance. Furthermore, innovative molecules and new therapeutic opportunities are presented, along with currently available therapies and ongoing clinical trials.
Lingua originaleEnglish
pagine (da-a)144-166
Numero di pagine23
RivistaSeminars in Cancer Biology
Stato di pubblicazionePubblicato - 2021


  • Innovative drugs
  • Ovarian cancer
  • Platinum resistance
  • Predictive biomarkers


Entra nei temi di ricerca di 'Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments'. Insieme formano una fingerprint unica.

Cita questo